Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SEER Program”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 973 records · Page 54Linked to original sources
PubMed2004

A report card on outcomes for surgically treated gastrointestinal cancers: are we improving?

INTRODUCTION: Longitudinal analyses of cancer registries provide an opportunity for population-based explanations of epidemiology and survival-related outcomes. This study used two population-based data sets to report on nine surgery-related cancers over the past three decades. MATERIALS AND METHODS: Using the SEER cancer database (1973-1999), all patients (>18 years old) with adenocarcinoma of esophagus, gastric, biliary system, pancreas, small bowel, colon, rectum; esophageal squamous cell carcinoma (ESC), or hepatocellular (HCC) carcinoma (n = 379,640) were analyzed. Changes in incidence rates, stage at diagnosis, and 5-year cancer and stage-specific survivals were determined. A separate database, the California inpatient database (1990-2000), was concurrently used to evaluate inpatient mortality after surgical resection (n = 34,057). RESULTS: Incidence rates increased for three cancers (esophageal, HCC, small bowel); decreased for three (rectal, gastric, ESC); and stayed constant for three (biliary, pancreatic, colon). More patients presented with local/regional disease in the 1990s versus 1970s for eight tumors (except small bowel, P < 0.05). Five-year overall survival improved for all but small bowel (P < 0.05); and local stage survival was improved for all except small bowel and biliary (P < 0.05). Finally, inpatient mortality rates improved significantly for liver, esophageal, pancreatic, and gastric resections (P < 0.05) over the past decade. CONCLUSIONS: For these nine surgically treated cancers, we are detecting disease at earlier and therefore more treatable stages, and surgical care and outcomes also appear to have improved. Continued reexamination of longitudinal trends of surgically relevant outcomes is important for future improvement of surgical care.

Databases, Factual↗
PubMed2006

Use of hormonal therapy in men with metastatic prostate cancer.

PURPOSE: Bilateral orchiectomy or luteinizing hormone releasing hormone agonists represent the standard of care for metastatic prostate cancer. In this population based study we assessed the use rates of these therapies in men who died of prostate cancer. MATERIAL AND METHODS: A total of 9,110 men 65 years or older who died of prostate cancer in 1991 to 2000 were identified through the population based Surveillance, Epidemiology and End Results, and Medicare linked database to determine hormonal therapy use rates. A modified Poisson regression model was used to estimate the adjusted effects of various factors associated with hormone use. RESULTS: Approximately 38% of black and 25% of white men did not receive hormonal therapy before dying of prostate cancer. After adjusting for cancer status at diagnosis and other potential confounding factors black race and residence in low income areas were associated with lower hormonal therapy use (relative risk 0.73, 95% CI 0.67 to 0.80 and 0.91, 95% CI 0.85 to 0.98, respectively). Hormonal therapy use was most comprehensive in the Northeast. CONCLUSIONS: A substantial number of men who die as a consequence of prostate cancer never receive hormonal therapy. The use of hormonal therapy varies significantly. Further studies are warranted to determine factors that may be associated with the incomplete use of hormonal therapy for metastatic prostate cancer.

Aged↗
PubMed2004

The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database.

Bronchioloalveolar carcinoma of the lung (BAC) is a subtype of adenocarcinoma of the lung. Although traditionally grouped with other non-small cell lung carcinomas (NSCLC), BAC has unique morphological features and clinical behavior such as bilateral lung involvement, indolent course and lack of association with smoking. Some epidemiologic studies report a significant increase in the incidence of BAC. We used the SEER database to compare the incidence, demographics, and overall survival of BAC patients as compared to other NSCLC types over the past two decades (1979-1998). Although the incidence of BAC has increased over the past two decades, BAC represents less than 4% of all NSCLC in every time period evaluated. The 1 year survival rate is significantly better for BAC patients relative to other histological subtypes of NSCLC. There has not been a marked increase in the incidence of BAC reported to SEER over the past 20 years.

Adenocarcinoma, Bronchiolo-Alveolar↗
PubMed2005

Prognostic impact of race and ethnicity in the treatment of colorectal cancer.

Numerous advances in the treatment of patients who have metastatic disease have improved colorectal cancer management, including new chemotherapeutic agents and combinations and targeted agents that modulate the efficacy of chemotherapy. Recent advances in the administration of irinotecan and oxaliplatin, in combination with 5-FU/LV, plus the addition of targeted agents bevacizumab and cetuximab have afforded steady increases in response rates and survival. Ongoing studies are evaluating the optimal sequencing and combinations of the agents described and the efficacy of new combinations in metastatic and adjuvant settings. Because the number of African-American patients in most clinical trials in colorectal cancer has been low, it is imperative that method increase participation so that new research developments reach all segments of the population.

Black or African American↗
PubMed2004

Contemporary staging and prognosis for primary tracheal malignancies: a population-based analysis.

OBJECTIVE: Determine staging characteristics and survival outcomes for primary malignancies of the trachea. Design Cross-sectional analysis of national cancer database. METHODS: Cases of primary tracheal malignancy were extracted from the Surveillance, Epidemiology, and End Results database for the time period 1988-2000. T-stage, N-stage, and overall stage of presentation were determined. Mean, median, and 5-year survival statistics were computed using Kaplan-Meier survival analysis for each tumor histology and for the overall cohort according to stage. RESULTS: Ninety-two cases with adequate histologic information were identified. Mean age at presentation was 59.3 years with an equal sex distribution. Squamous cell carcinoma was the most common tumor type (41 cases) followed by adenoid cystic carcinoma (19 cases). Forty-nine cases (53%) presented with stage 3 or stage 4 disease. Squamous cell carcinoma exhibited poorer survival (mean survival, 44.0 month, 5-year survival, 34%) than adenoid cystic carcinoma (mean survival, 115 month, 5-year survival, 78%). Five-year unadjusted survival rates according to overall stage were 52.8%, 70.0%, 75.0%, 15.1%, respectively. CONCLUSIONS: Primary tracheal malignancies often present with advanced stage. Patients with squamous cell carcinoma of the trachea have poorer prognoses when compared with adenoid cystic carcinoma and other tumor types. Staging tracheal cancer with a TNM-based system helps predict survival. EBM RATING: C.

Carcinoma, Adenoid Cystic↗
PubMedDate not supplied

Patterns in cancer incidence among American Indians/Alaska Natives, United States, 1992-1999.

OBJECTIVE: Cancer is a major public health concern in American Indian and Alaska Native (AI/AN) communities. However, information on the incidence of cancer is lacking for this group. The purpose of this study is to report cancer incidence patterns for the U.S. AI/AN population. METHODS: Age-adjusted annual cancer incidence rates for 1992 through 1999 were calculated for 12 Surveillance, Epidemiology and End Results (SEER) areas, representing a sample (42%) of the U.S. AI/AN population. Trends in cancer incidence rates for the AI/AN sample were determined using standard linear regression of log-transformed rates and were compared to those of the U.S. white population. RESULTS: The top five incident cancers (from highest to lowest) among AI/AN males were prostate, lung and bronchus, colon and rectum, kidney and renal pelvis, and stomach cancers. Among AI/AN women, cancers of the breast, colon and rectum, lung and bronchus, endometrium, and ovary ranked highest. Four sites where cancer incidence rates are greater for AI/ANs than for whites include gallbladder (the AI/AN rate was 4.1 times the rate for white males and 2.6 times the rate for white females), liver and intrahepatic bile duct cancers (1.3 times for males and 2.3 times for females), stomach (1.2 times for males and 1.5 times for females), and kidney and renal pelvis (1.03 times for males and 1.07 times for females). The data show increasing trends for AI/AN males and females and declining trends for white males and females for colorectal, stomach, and pancreatic cancers and leukemia. Similar differences between AI/AN rates and white rates were found for urinary bladder cancers in males and gallbladder cancer in females. CONCLUSIONS: Analysis of SEER data allowed for the determination of disparities in cancer incidence between a sample of the U.S. AI/AN population and the white population. The findings of this study provide baseline information necessary for developing cancer prevention and intervention strategies specific to the AI/AN population to address these cancer disparities.

Adult↗
PubMed2006

Linkage study of cancer risk among lead-exposed workers in New Jersey.

OBJECTIVES: Epidemiologic studies have illustrated a possible association between occupational exposure to lead and cancer, specifically cancers of the kidney, lung, stomach, and nervous system. We performed a linkage between two New Jersey databases: the Adult Blood Lead Epidemiology and Surveillance System (ABLES) and the New Jersey State Cancer Registry (NJSCR) for 1985-2001 to ascertain the risk of cancer in lead-exposed workers and to evaluate the usefulness of this type of linkage. METHODS: A cohort of 3192 men from the ABLES database met the selection criteria before the linkage. AUTOMATCH was used to link the two databases. Person-time was stratified for each worker by five-year age group and calendar year. A standardized incidence ratios (SIR) analysis was performed. RESULTS: 83 cases of cancer were found among 3165 men after all exclusions were made. Workers were followed for an average of ten years and contributed 30,401 person-years. The SIR analysis showed a large overall deficit of cancer (SIR=0.51; 95% CI 0.41 to 0.62). Cancers of the stomach, breast, larynx, intrahepatic bile duct, and chronic myeloid leukemia were non-significantly elevated. Prostate cancer showed the only statistically significant result, a deficit with an SIR of 0.35 (95% CI 0.20 to 0.57). Deficits also occurred in cancers of the lung, kidney, and brain. CONCLUSIONS: The results do not indicate that occupational exposure to lead is associated with cancer. However, firm conclusions are not possible because of various study limitations, including small numbers, a large percentage of workers without age information, short follow-up time, and lack of vital status information. Cancer incidence in this cohort was expected to be low due to the Healthy Worker Effect and young age. Further follow-up of this cohort may be warranted since additional cancers may accrue as time from first exposure increases. Increased worker cohort information would also improve this type of study.

Adolescent↗
PubMed2005

Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment.

There is a critical disconnect between what we discover and what we deliver to all Americans in the form of prevention, screening, detection, diagnosis, and treatment of cancer. We must identify and eliminate all barriers that prevent the benefits of research from reaching all people. Such barriers may be experienced at any point along the continuum of prevention, screening, diagnosis and treatment, and palliative care. In communities of low socioeconomic status, patient navigation has proved to be an effective intervention in promoting such timely diagnosis and treatment when applied at the point of abnormal finding. Geographic areas with excess cancer mortality should be delineated and targeted with an intense approach to providing culturally relevant education, appropriate access to screening diagnosis and treatment, and improved support systems, including navigation.

Culture↗
PubMed2004

AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States.

BACKGROUND: The optimal extent of thyroidectomy for well-differentiated thyroid cancer is controversial. It has been suggested that surgeons use the Age, Metastases, Extent and Size (AMES) risk classification to decide between partial thyroidectomy (PT) or total thyroidectomy (TT). METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients who underwent PT or TT for well-differentiated thyroid cancer between 1992 and 1997. Age, distant metastases, extrathyroidal extension, tumor size, AMES risk group, gender, histologic subtype, and lymph node metastases were analyzed by using logistic regression models to evaluate whether surgeons use these factors to determine extent of thyroidectomy. RESULTS: Of 9,226 patients, most patients had small cancers confined to the thyroid gland. Of these, 79.9% were AMES low-risk, and 83% underwent TT. Age 40 years or older (40 to 49 years: odds ratio [OR], 0.75, 95% confidence interval [CI], 0.65 to 0.86; 50 years or older: OR, 0.66; 95% CI, 0.58 to 0.75) was associated with a lower likelihood of TT, as were female gender (OR, 0.80; 95% CI, 0.70 to 0.92) and follicular histology (OR, 0.65; 95% CI, 0.55 to 0.78). Extrathyroidal extension (OR, 3.85; 95% CI, 3.09 to 4.80), regional lymph node metastases (OR, 6.98; 95% CI, 5.45 to 8.93), distant metastases (OR, 7.29; 95% CI, 2.69 to 19.8), AMES high-risk group (OR, 2.82; 95% CI, 2.36 to 3.38), and larger tumor size (OR, 1.27; 95% CI, 1.01 to 1.59) were associated with greater likelihood of TT. In multivariable analyses, only age, extrathyroidal extension, and regional and distant metastases were associated with extent of thyroidectomy; AMES risk group and tumor size were no longer significant. CONCLUSIONS: Most patients undergo TT for well-differentiated thyroid cancer regardless of AMES risk grouping. In contrast to AMES risk-group classification, younger patients are more likely to undergo TT compared with older patients. Although extrathyroidal extension and distant metastases were associated with TT in accordance with AMES criteria, tumor size had no independent influence. Regional lymph node metastasis, not an AMES criterion, increased the likelihood of TT. Some components of AMES risk-group classification are used by surgeons to choose the extent of thyroidectomy.

Adenocarcinoma, Follicular↗
PubMed2004

Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.

BACKGROUND: Diagnostic tests cannot reliably distinguish malignant from benign pheochromocytomas. Laparoscopic adrenalectomy for pheochromocytomas >6 cm is controversial because of a perceived increased risk of malignancy that is based on anecdotal reports and small series. The aim of this study was to determine if pheochromocytoma size should affect the choice of surgical approach. METHODS: Malignant pheochromocytomas in the Surveillance Epidemiology and End Results (SEER) database (1988-2000) were compared to benign pheochromocytomas in our institutional database (1993-2003). The sensitivity, specificity and likelihood ratio for tumor size to predict malignancy were calculated for both groups. RESULTS: Ninety malignant and 60 benign pheochromocytomas were compared. Overall, malignant pheochromocytomas were larger than benign pheochromocytomas (7.6 +/- 4.2 cm vs 5.3 +/- 2.3 cm). However, tumor size was not significantly different between malignant pheochromocytomas without local invasion or metastases and benign pheochromocytomas (6.1 +/- 3.1 cm vs 5.3 +/- 2.3 cm). In pheochromocytomas with local disease only, maximum likelihood ratio to predict malignancy was at a tumor size of greater than 8 cm (2.84). CONCLUSIONS: Although risk of malignancy increases with size for all pheochromocytomas, size does not reliably predict malignancy in pheochromocytomas with local disease only. Regardless of tumor size, laparoscopic adrenalectomy for pheochromocytoma should be converted to open adrenalectomy for difficult dissection, invasion, adhesions, or surgeon inexperience.

Adolescent↗
PubMed2005

The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart.

BACKGROUND: This population study compared the treatment and prognosis of Hürthle cell follicular thyroid carcinoma (HCFC) and non-HCFC. METHODS: The Surveillance, Epidemiology and End Results database identified patients with HCFC and non-HCFC from 1988 to 1993 who were followed to 2001. Treatment of each carcinoma was compared, and the effect of prognostic factors on survival was analyzed. RESULTS: Eight hundred forty-five patients were identified; 172 patients (20%) had HCFC and 673 patients (80%) had non-HCFC. Total thyroidectomy was performed in 80% of patients with HCFC compared with 69% with non-HCFC (P = .005). Radioactive iodine was used in 33% with HCFC and 45% with non-HCFC (P = .003). The crude 10-year survival was 73% in HCFC and 83% in non-HCFC patients. Older age (> or =50 vs <50 years; hazard ratio, 6.35; 95% CI, 4.07-9.93), men (hazard ratio, 2.07; 95% CI, 1.52-2.81), larger tumor size (>5 vs < or =5 cm; hazard ratio, 2.20; 95% CI, 1.55-3.13; >10 cm vs < or =5 cm; hazard ratio, 3.28; 95% CI, 1.12-9.61), nodal metastases (hazard ratio, 3.11; 95% CI, 1.80-5.37), and distant metastases (hazard ratio, 3.91; 95% CI, 1.94-7.90) were associated with a higher mortality rate. Histologic type (non-HCFC vs HCFC; hazard ratio, 0.85; 95% CI, 0.60-1.19; P = .34), local extension, extent of thyroidectomy, and radioactive iodine use had no effect on the mortality rate. CONCLUSIONS: Histologic distinction between HCFC and non-HCFC is not as prognostically important as age, gender, and tumor stage. This study suggests that patients with HCFC should be treated the same as patients with equivalent stage non-HCFC.

Adenocarcinoma, Follicular↗
PubMed2005

Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid.

BACKGROUND: The use of radioactive iodine (RAI) in patients with follicular thyroid carcinoma is well established. How its use affects patient outcome and which patients benefit is understood poorly. This study seeks to determine how RAI influences survival and to delineate the populations that are impacted most. METHODS: The Surveillance, Epidemiology, and End Results database is a sample of approximately 14% of the US population. It was used to identify patients with follicular thyroid carcinomas and the treatment that they received. Factors such as the presence of lymph node and distant metastases, age, and tumor size were included for analysis. RESULTS: A total of 4317 patients were identified with follicular thyroid carcinoma. Of these, the records of 2112 patients who were entered in the study after 1988 contained the required data and were included for analysis. Median follow-up time was 95 months. Factors that were associated with increased risk of death included distant metastatic disease, cervical lymph node disease, and the lack of RAI use. Protective factors were tumor size of <2 cm and age of <45 years. Some patients with a greater number of risk factors benefited from RAI. CONCLUSION: RAI provides survival benefit to some patients with follicular carcinoma of the thyroid. The greatest improvements were seen in those patients with locoregional or distant disease spread.

Adenocarcinoma, Follicular↗
PubMed2006

Outcomes of adrenal cortical carcinoma in the United States.

BACKGROUND: Improvements in the sensitivity of radiographic imaging have lead to an increase in the number of adrenal masses diagnosed. The purpose of this study is to determine if technologic advancements have resulted in the diagnosis of earlier-staged adrenal cortical cancer (ACC) and to determine if the survival of patients with ACC has improved over the past 15 years. METHODS: Patients with ACC were identified in the Surveillance, Epidemiology, and End Results database between 1988 and 2002. Changes in demographics, stage, size, and treatment were analyzed by standard statistical testing. RESULTS: We identified 602 patients with a mean age of 53 years and an average tumor size of 11.8 cm. Two hundred thirty-eight (39.5%) patients presented with localized disease (stages I and II), and 311 (52%) patients presented with advanced disease (stages III and IV). The comparison of smaller lesions and number of patients were 5 to 6 cm in 24 (4%) patients, 4 to 5 cm in 27 (4.5%) patients, and <4 cm in 19 (3.1%) patients. Patients with masses less than 5 cm were statistically more likely to have localized disease (P <. 001). Age (P = .10), tumor size (P = .85), tumor stage (P = .45), and 5-year survival (P = .5) did not change over the 15-year study. CONCLUSIONS: Over the 15-year study, patients with ACC were not diagnosed at an earlier stage or with tumors smaller, and survival did not improve.

Adrenal Cortex Neoplasms↗
PubMed2004

Geographic distribution of prostate cancer incidence in the era of PSA testing, Connecticut, 1984 to 1998.

OBJECTIVES: To evaluate the geographic variation of prostate cancer incidence in Connecticut during a 15-year period: before the introduction of prostate-specific antigen (PSA) testing (1984 to 1988), during its introduction (1989 to 1993), and after its widespread adoption (1994 to 1998). METHODS: A spatial scan statistic was used to detect and test the significance of the geographic rate variation among 29,944 incident cases. RESULTS: During 1984 to 1988, eight locations had incidence rates that differed significantly from the statewide level; for 1989 to 1993, only two locations were identified. By 1994 to 1998, a significant rate variation was noted for 10 locations around Connecticut. CONCLUSIONS: The observed geographic variation of incidence rates may reflect differing opportunities to uncover latent cases at given locales.

Adenocarcinoma↗
PubMed2004

Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.

OBJECTIVES: To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999. METHODS: We used a database linking the Surveillance, Epidemiology, and End Results (SEER) registry with Medicare claims to extract treatment information for 90,128 men aged 65 years and older, who were newly diagnosed with nonmetastatic prostate cancer. RESULTS: The use of aggressive therapy has increased among white men over time; but aggressive therapy has recently declined among African-American men. Accounting for age, grade, socioeconomic status, and comorbidity, African-American men were 26% less likely to receive aggressive therapy than white men (odds ratio 0.74; 95% confidence interval 0.70 to 0.79). The use of ADT has increased substantially in both the primary and the adjuvant settings. By 1999, 45.6% of white men and 35.8% of African-American men who selected conservative management received primary ADT; among men treated with external beam radiotherapy, the proportion receiving adjuvant ADT was 53.7% for white men and 42.4% for African-American men (P <0.001). CONCLUSIONS: Racial differences in the use of aggressive and conservative therapies are increasing. ADT is becoming a widely adopted component of initial treatment for localized prostate cancer. It is crucial to understand the impact of treatment patterns, including the increased use of ADT, on patient survival, morbidity, and costs of care.

Aged↗
PubMed2005

Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database.

OBJECTIVES: To analyze the additional impact of retroperitoneal lymphadenectomy on overall and cancer-specific survival (CSS) in patients with primary renal cell carcinoma (RCC) undergoing radical nephrectomy. The benefit of regional lymphadenectomy in patients with primary RCC remains controversial. METHODS: Of 33,016 patients diagnosed with primary RCC between 1983 and 1998, a subset of 4453 underwent radical nephrectomy with or without regional lymphadenectomy. The extent of lymphadenectomy was assessed using the number of nodes examined, and the tumor burden was assessed using the number of positive nodes and the ratio of the number of positive nodes to the total number of nodes examined. Associations between CSS and the number of nodes examined, number of positive nodes, and ratio of the number of positive nodes to the total number of nodes examined were assessed. RESULTS: An inverse correlation was found between the likelihood of CSS and the number of nodes examined, particularly for those with regional disease even after controlling for other factors. A correlation was noted between the number of nodes examined and the number of positive nodes. Significant differences in CSS were observed in node-negative patients with regional disease compared with node-positive patients. An increasing nodal burden was associated with worse CSS. CONCLUSIONS: More extensive lymphadenectomy does not appear to increase further the probability of CSS in patients undergoing radical nephrectomy for RCC. An increased number of positive nodes, as well as an increasing nodal burden, although associated with a lower likelihood of survival, were not independent predictors of RCC-specific mortality.

Adult↗